Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EYESEE

Financiado

Cerrado

Development of new gene therapy approaches for the treatment of ocular neovascul...

Development of new gene therapy approaches for the treatment of ocular neovascularization Ocular neovascularization (NV) is the pathological feature common to Retinopathy of Prematurity, Diabetic Retinopathy, and Age-related Macular Degeneration. Collectively, these diseases are the leading cause of blindness in develo... ver más

31/10/2013

UALG

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

UNIVERSIDADE DO ALGARVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UALG

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSIDADE DO ALGARVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ocular neovascularization (NV) is the pathological feature common to Retinopathy of Prematurity, Diabetic Retinopathy, and Age-related Macular Degeneration. Collectively, these diseases are the leading cause of blindness in developed countries, and even more relevant due to the increased life expectancy. Current therapies can delay the progression of the disease, but do not restore the vision already lost. Therefore, there is a need for new, more efficient anti-angiogenic therapies. Gene therapy has been successfully used in several ocular disease paradigms. Most gene therapy strategies have used viral vectors due to their gene transfer efficiency. Nevertheless, viral vectors have several limitations, the most important ones the risk of random integration into the genome and potential severe immune response. Non-viral vectors have the potential to overcome the drawbacks associated with viral vectors but, to date, non-viral vectors still lag behind viral ones in gene transfer efficiency. This proposal aims to address both the need for new therapeutic strategies to treat ocular NV and development of new non-viral vectors optimized for ocular gene therapy. This dual approach would be feasible due to the multidisciplinary background of the Coordinator of this proposal in gene therapy, biology and and materials science. This project will study the potential of combining the inhibition of angiogenic factors and the expression of anti-angiogenic factors, delivered by the developed non-viral vectors. The outcome of this project would be two-fold: 1) non-viral vectors with an efficiency comparable to viral ones and 2) new therapeutic strategies to prevent loss of vision caused by the progression of ocular NV. This can significantly contribute to European excellence by decreasing the knowledge gap and generate added value products that can simultaneously have an economic impact but mostly have a social impact, specially in those ailing from diseases causing blindness

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores